Camilla Caputo

Dr. Camilla Caputo

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
VMVincenzo La Mura
Vincenzo La Mura
NBNiccolò Bitto
Niccolò Bitto
CCCecilia Capelli
Cecilia Capelli
CCCamilla Caputo
Camilla Caputo
SSSimona Siboni
Simona Siboni
FPFlora Peyvandi
Flora Peyvandi
Ruling out advanced fibrosis/cirrhosis is mandatory for persons with hemophilia (PWH) who are candidates for gene therapy. However, clinical evaluation and noninvasive tests (NITs) may be inaccurate after hepatitis C virus (HCV) clearance. We conducted a prospective hepatological screening to detect advanced fibrosis/cirrhosis in PWH after HCV clearance. Any risk factor of chronic liver damage was registered by using biochemical data, liver stiffness measurement (LSM), and ultrasound (US). A pre/post-HCV clearance analysis was conducted prospectively in a subgroup of patients who underwent LSM, US, and NITs for fibrosis. We evaluated 119 patients (median age, 53 years; range, 36-87 years) with a previous HCV infection (hemophilia A, n = 108; hemophilia B, n = 11). Ninety-six (81%) presented at least 1 potential risk factor of chronic liver damage. Metabolic risk factors were the most prevalent, with 51 patients (44%) having US steatosis. In 21 patients (18%), clinical, biochemical, liver morphology, and/or LSM were suggestive of advanced fibrosis/cirrhosis. Furthermore, 10 patients (8%) had esophageal varices and 3 (3%) had hepatocellular carcinoma. In 57 patients included in the prospective analysis, LSM and NITs were reduced after HCV clearance (P < .05), but US signs specific of cirrhosis remained unchanged. Overall, 23 of 80 patients (29%) with LSM <10 KPa had at least 1 US sign suggestive of advanced fibrosis/cirrhosis. A similar proportion (18%) was observed for LSM <8 KPa. Overall, risk factors of chronic liver damage are frequent after HCV clearance, but changes in LSM and NITs after clearance may be inaccurate to rule out advanced fibrosis/cirrhosis. A specific diagnostic workup is warranted to evaluate liver health in PWH in the era of gene therapy.

25 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NBNiccolò Bitto
Niccolò Bitto
GGGabriele Ghigliazza
Gabriele Ghigliazza
SLSTANISLAO LAVORATO
STANISLAO LAVORATO
CCCamilla Caputo
Camilla Caputo
VMVincenzo La Mura
Vincenzo La Mura
Portal hypertension is the consequence of cirrhosis and results from increased sinusoidal vascular resistance and hepatic blood inflow. Etiological therapies represent the first intervention to prevent a significant increase in portal pressure due to chronic liver damage. However, other superimposed pathophysiological drivers may worsen liver disease, including inflammation, bacterial translocation, endothelial dysfunction, and hyperactivation of hemostasis. These mechanisms can be targeted by a specific class of drugs already used in clinical practice. Albumin, rifaximin, statins, aspirin, and anticoagulants have been tested in cirrhosis and were a topic of discussion in the last Baveno consensus as non-etiological therapies. Based on the pathogenesis of portal hypertension in cirrhosis, our review summarizes the main mechanisms targeted by these drugs as well as the clinical evidence that considers them a valid complementary option to manage patients with cirrhosis and portal hypertension.

14 September 2026 in Liver International
Verified
Journal Article
Open access
PDF file
NBNiccolò Bitto
Niccolò Bitto
GTGiulia Tosetti
Giulia Tosetti
ATArmando Tripodi
Armando Tripodi
ALAnna Lecchi
Anna Lecchi
SMSilvia La Marca
Silvia La Marca
VMVincenzo La Mura
Vincenzo La Mura
Background & Aims: Conventional laboratory tests do not capture platelet–vessel wall interactions (primary haemostasis) occurring in vivo, limiting guidance before invasive procedures. This is relevant in patients with thrombocytopenia, hallmark of advanced cirrhosis. Microfluidic assays may overcome these limitations. The Total Thrombus Analysis System (T‐TAS) is a flow chamber that can be adapted for thrombocytopenic samples when equipped with the HD‐CHIP. The CirTAS study aimed to assess T‐TAS reproducibility and the ability to identify a disease‐severity gradient in patients with cirrhosis and thrombocytopenia. Methods: Eighty‐one patients with cirrhosis and thrombocytopenia were enrolled (20 Child–Pugh A, 41 B/C and 20 B/C with bacterial infection). T‐TAS measurements were performed using the HD‐CHIP. Reproducibility was assessed by intraclass correlation coefficients. Thromboelastometry (ROTEM) parameters were analysed in parallel. Multivariable and piecewise regression analyses were performed to test factors influencing T‐TAS parameters. Results: T‐TAS showed high reproducibility, with intraclass correlation coefficients ≈0.90 for all parameters ( p < 0.001), even in platelet counts < 50 × 10 9 /L. Thrombus formation under flow declined with worsening clinical status and presence of bacterial infection ( p < 0.05). Alongside, ROTEM showed a trend towards hypocoagulability with increasing disease severity and correlated with T‐TAS parameters. Platelet count and factor VIII (FVIII) were independent determinants of the most representative T‐TAS parameters. Exploratory analyses detected a trend towards a stronger platelet count‐T‐TAS association at 30–50 × 10 9 /L. Conclusions: T‐TAS is reproducible in thrombocytopenic cirrhosis and is associated with reduced thrombus formation alongside disease progression and bacterial infection. Platelet count and FVIII are the main determinants of thrombus formation assessed by T‐TAS.